MSB 3.19% 97.0¢ mesoblast limited

banter and General Discussion, page-8350

  1. 12,360 Posts.
    lightbulb Created with Sketch. 3370
    @irenekwshiu
    This is my understanding, and happy for it to be corrected.

    I think the FDA are looking at a few aspects, in particular a balance between clinical evidence and potency assays

    For GHVD pediatric, most of the data is based on study 001, which is a single-arm trial.
    Given that scientifically, single-arm trial data are weaker evidence than a RCT - the FDA then puts more emphasis on the potency assay.
    That's where we are with Rex-L (Ryoncil).

    But, for CLBP and CHF, mesoblast have conducted RCTs - so, I would take it that as long as the RCT data is good the FDA would require less from these potency assays for Rex-L when compared to Rem-L (Ryoncil).
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
0.030(3.19%)
Mkt cap ! $1.107B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $3.342M 3.477M

Buyers (Bids)

No. Vol. Price($)
4 33313 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 73982 2
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.